Clinical trial · people
SS-31: 96.1 m longer 6-minute walk at 168 weeks in TAZPOWER
Checked against the paper Clinical trialPublished by PepVault
The takeaway
For Barth syndrome, this small extension suggests elamipretide's gains in walking distance and fatigue held up through 168 weeks, with injection-site reactions as the most common side effect.
- Kind
- Clinical trial
- Studied in
- People
- Published
- 2024
- Journal
- Genet Med
What they tested
The team wanted to know whether elamipretide (SS-31) stays safe and keeps working over the long term in people with Barth syndrome.
How the study was done
An open-label extension, where everyone knew they were on the drug, followed a 28-week randomized, placebo-controlled trial called TAZPOWER. Patients who entered the extension kept taking the trial's 40 mg dose of elamipretide under the skin each day for up to 168 weeks, and 8 of them reached the week 168 visit.

What they found
Elamipretide was well tolerated, and reactions at the injection site were the most common side effect. The 6-minute walk test, which measures how far a person walks in 6 minutes, improved significantly at every visit compared with the start of the extension, reaching a total gain of 96.1 m at week 168. Average scores on a Barth syndrome fatigue questionnaire stayed better than at the start at every visit. Heart volumes measured by 3D echocardiography, an ultrasound of the heart, trended significantly toward improvement by week 168, and the MLCL/CL biomarker ratio also improved and tracked with key clinical outcomes.
What it doesn’t show
This was a very small group, with only 8 people reaching the final visit, and the extension had no placebo arm, so the gains can't be cleanly separated from other causes. Patients and doctors knew the treatment, which can shape how symptoms like fatigue are rated.
The paper
Thompson et al. Long-term efficacy and safety of elamipretide in patients with Barth syndrome: 168-week open-label extension results of TAZPOWER. Genet Med. 2024.
The compound
More studies on SS-31
- SS-31 (elamipretide) eye drops missed main vision goal in LHON trialRandomized trial · people · 2024
- SS-31: no gain in walk distance or fatigue in the MMPOWER-3 trialRandomized trial · people · 2023
- SS-31: wearable data grouped responders with 100% accuracyRandomized trial · people · 2023
- SS-31: no 12-week benefit, walk gains by 36 weeks open-labelRandomized trial · people · 2021
- SS-31 raised muscle ATP capacity after one dose in older adultsRandomized trial · people · 2021
- SS-31: walk distance rose with dose in 5-day MMPOWER trialRandomized trial · people · 2018
- Every study on SS-31
Researched and drafted with AI, then checked claim by claim against the primary sources linked below by a separate review pass. Published by PepVault. Last reviewed . Spot an error? feedback@pepvault.app. How we research. This page reports one study; it is not medical advice.